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Abstract
Background: The enhancer of zeste-homolog 2 (EZH2) is involved in cancer development through gene silencing
by trimethylation of lysine 27 of histone 3 (H3K27me3). The C/C genotype for the EZH2 rs3757441 single-nucleotide
polymorphism (SNP) is linked with poor prognosis in metastatic colorectal cancer (CRC), but molecular and
pathological characterization of this SNP is lacking.
Methods: 119 primary CRCs were analyzed. SNP was evaluated by real-time PCR from colonic healthy tissue, while
EZH2 and H3K27me3 expression were studied by immunohistochemistry. We primarily looked for correlation between
EZH2 rs3757441 genotypes and EZH2/H3K27me3 expression. Potential associations between EZH2/H3K27me3
expression and clinico-pathological features or KRAS exon 2 and BRAF exon 15 mutations were secondary
endpoints. Statistical analysis was performed by chi-square test, T-test or ANOVA.
Results: The C/C genotype was significantly associated with higher EZH2 (100 vs. 44 %; P = 0.019) and H3K27me3
(100 vs. 38 %; P = 0.009) staining intensity compared with C/T and T/T. EZH2 3+ staining significantly correlated
with stronger H3K27me3 expression (P = 0.039). KRAS and BRAF mutations were not associated with EZH2 or
H3K27me3 expression.
Conclusion: EZH2 rs3757441 C/C genotype is associated with stronger EZH2 and H3K27me3 immunoreactivity in
primary CRC: this SNP may serve as a promising biomarker for EZH2-targeting agents and may add independent
information to KRAS and BRAF testing.
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Background
Colorectal cancer (CRC) is one of the leading causes of
cancer-related deaths worldwide [1]. Validated predictive
or prognostic biomarkers in metastatic CRC (mCRC) are
limited to RAS and BRAF mutations [2, 3]. There is
therefore a dire need for a deeper characterization of
CRC biology and for the identification of innovative
therapeutic targets.
Epigenetics offers a different perspective to understand
cancer biology, complementing the conventional genetic
approach [4]. Polycomb Group genes (PcGs) represent
some of the most studied components of the epigenetic
machinery. PcGs are organized in two major Repressive
Complexes (PRCs) and induce gene silencing through
histone post-translational modifications [5]. Most PcGs
have been involved in the initiation and promotion of
cancer and contribute to drug resistance in both haem-
atological and solid malignancies [6].
EZH2 is the catalytic subunit of PRC2, which catalyzes
histone H3 trimethylation on lysine 27 (H3K27me3),
thereby promoting selective gene silencing in normal
stem cells and cancer cells. This epigenetic modification
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is responsible for several key events in tumor develop-
ment, including the occurrence of distant metastases
and angiogenesis [6, 7]. We have recently investigated
the role of EZH2 single-nucleotide polymorphisms
(SNPs) in mCRC patients treated with chemotherapy
plus bevacizumab: the C/C genotype for the rs3757441
SNP was associated with worse prognosis in terms of
progression-free and overall survival [8]. This finding
was subsequently confirmed in patients treated with
chemotherapy alone, an evidence suggesting a prognos-
tic significance of this SNP in mCRC [9]. We hypothe-
sized that the C/C genotype would create a transcription
factor-binding site, thereby increasing the expression of
the oncogenic EZH2 protein [8]. However, a definitive
characterization of rs3757441 is still missing, since correl-
ation between the SNP variants and EZH2/H3K27me3
protein expression in CRC samples has not been reported.
In the present study, we analyzed EZH2 rs3757441 geno-
type, EHZ2/H3K27me3 expression and pathological and
molecular characteristics of 119 primary CRC samples.
Methods
Sample selection and DNA isolation
Consecutive CRC patients who underwent surgery on
primary tumor and had their samples available for ana-
lyses at a single Institution (Unit of Pathology, Pisa)
were identified. All patients provided written informed
consent for sample collection and analysis. The study
was conducted in accordance to the Declaration of
Helsinki and the protocol was approved by the Ethics
Committee of Pisa University Hospital. A total of 119
formalin-fixed paraffin-embedded tissues of primary
CRCs were used for DNA extraction. DNA used for
SNP analysis was extracted from normal colonic tissue,
while tumor DNA was sequenced for KRAS and BRAF
analyses. DNA was isolated using the QIAamp DNA
Mini Kit (QIAGEN), following manufacturer’s instruc-
tions. Concentration and purity of DNA were measured
through a spectrophotometer.
Genetic analyses
Researchers who were not aware of EZH2 and H3K27
immunohistochemistry results and were blinded to
patients’ clinical data performed genetic analyses.
EZH2 SNP [c.626–394C > T (rs3757441)] was analyzed
through real-time PCR, as previously described [8].
KRAS exon 2 (codon 12–13) and BRAF exon 15 (codon
600) mutations were detected via real-time sequencing
using PyroMark Gold Q96 reagents (QIAGEN) on Pyro-
MarkTM Q96 ID instrument (Biotage, Sweden), as
reported elsewhere [10]. Results were analyzed with Pyro-
Mark Q24 1.0.9 software.
EZH2 and H3K27 immunohistochemistry
Immunohistochemistry was performed on formalin
fixed, paraffin-embedded tumor tissues, using previously
validated protocols for both antibodies [11]. Involved
pathologist carefully reviewed all CRC samples and se-
lected tumor sections which were most representative of
each tumor. Briefly, 5 μm-thick tissue sections were
deparaffinized in xylene and rehydrated in a graded
ethanol series. Slides were stained using a diaminoben-
zidine detection system preceded, only for EZH2, by
heat-induced epitope retrieval involving immersion of
tissue sections in a pre-warmed buffer solution (Target
Retrieval Solution, DakoCytomation, Carpinteria, CA)
and maintaining heat in a steamer at 988 °C for 50 min.
To reduce nonspecific staining caused by endogenous
biotin, the Endogenous Biotin Blocking Kit (Ventana
Medical Systems, SA, Illkirch, Cedex, France) was
employed, according to Manufacturer’s instructions.
EZH2 and H3K27me3 immunostaining was performed
using monoclonal antibodies by Abcam (1:100 dilution
and 1:50 dilution, respectively). Negative controls were
obtained by omission of the primary antibodies.
Two pathologists were responsible for immunohisto-
chemical evaluation and provided independent scoring
results for both EZH2 and H3K27. In case of discrep-
ancy, joint revision of the ambiguous samples was per-
formed to assure the consistency of definitive results.
EZH2 expression was categorized as: i) percentage of
positive cells (0-100 %, evaluated as a continuous variable):
the percentage of positive cells for each sample was deter-
mined as the average value of positive cells in 10 fields
(approximately 100 cells per field were counted) at 10
High Power Field (HPF); ii) staining intensity, evaluated
by a validated system [12]: we classified all cases in 4
categories [(−) less than 10 % positive cells, any intensity;
(1+) from 10-25 %, any intensity; (2+) from 25-75 %, any
intensity; (3+) greater than 75 %, any intensity]; iii) Stain-
ing Index (SI), a semiquantitative method, evaluating both
the heterogeneous distribution of positive cells and the
differing intensity of the staining simultaneously: as de-
scribed by Fluge et al. [13], SI is calculated as the product
(0 to 9) of positive cells (0, 0 %; 1, < 10 %; 2, 10–50 %; and
3, > 50 %) and staining intensity (negative to 3+).
H3K27me3 expression was scored as follows: i) per-
centage of positive cells (0 - 100 %); ii) staining intensity
(as described for EZH2). In both cases, the pathologist
performing immunohistochemistry analyses was blinded
from genetic data.
Statistical analysis
EZH2 and H3K27 expression intensities were corre-
lated with clinical and molecular features by means of
chi-square test, T-test or ANOVA (as appropriate; sig-
nificance was set at P < 0.05 for two-tailed tests).
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Neither pathologists performing immunohistochemis-
try nor molecular biologists performing genetic evalu-
ation were directly involved in statistical analyses, which
were conducted by independent investigators.
Results
EZH2 and H3K27me3 expression
Results of the expression analysis (Figs. 1, 2) are sum-
marized in Table 1. Prevalence of different SNP geno-
types was in line with published data in Caucasian
populations. Mean number of EZH2 or H3K27me3
positive cells was 46.2 % (standard deviation, SD: 28.99)
and 64.2 % (SD: 29.10), respectively. KRAS-BRAF muta-
tions occurred as expected from previous reports.
Correlation of EZH2 rs3757441 variants with EZH2/
H3K27me3 expression
Our primary goal was to investigate potential correlations
between rs3757441 variants and EZH2/H3K27me3 ex-
pression. Moving from our previous reports [8, 9], we
explored the association between protein expression and
each genotype. Subsequently, we grouped the C/T and T/T
genotypes (previously associated with better prognosis) and
compared them with the C/C genotype (Table 2).
We found significant differences among the three ge-
notypes in terms of both EZH2 (3+ samples: 100 % vs.
39 % vs. 48 %; P = 0.028) and H3K27me3 (3+ samples:
100 % vs. 35 % vs. 40 %; P = 0.022) staining intensity.
When the C/T and T/T cases were grouped, the sam-
ples harbouring the C/C genotype showed significantly
stronger EZH2 positivity compared to other genotypes
(3+ samples: 100 % vs. 44 %, respectively; P = 0.019).
The same significant association was reported for
H3K27me3 (3+ samples among C/C vs. C/T or T/T:
100 % vs. 38 %; P = 0.009). Moreover, we observed a trend
toward higher percentage of EZH2 positive cells (60.0 %
vs. 46.0 %; P = 0.288) and higher SI (SI 4–9: 100 % vs. 72%;
P = 0.322) in C/C cases compared to C/T or T/T cases.
Correlation of EZH2 rs3757441 variants with clinical and
molecular characteristics
The C/C genotype was associated with higher tumor
grade: all the 5 cases were scored as grade 3–4 tumors,
while undifferentiated histology was reported in 37 % and
38% of the C/T and T/T cases, respectively (P = 0.021)
(Additional file 1: Table S1). We also observed a higher in-
cidence of BRAF mutation among T/T cases (16 % vs. 0 %
and 2 % among C/C and C/T, respectively; P = 0.030).
Fig. 1 Different EZH2 staining intensity at immunohistochemistry. EZH2 negative (panel a), EZH2 2+ (panel b) and EZH2 3+ (panel c) cases are
shown. Negative: no staining; 1+ (not shown): faint and barely perceptible staining; 2+: incomplete, weak to moderate staining; 3+: uniform, complete
and intense staining
Fig. 2 Different H3K27me3 staining intensity at immunohistochemistry. H3K27me3 negative (panel a), H3K27me3 2+ (panel b) and H3K27me3 3+
(panel c) are shown. Negative: no staining; 1+ (not shown): faint and barely perceptible staining; 2+: incomplete, weak to moderate staining; 3+:
uniform, complete and intense staining
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Correlation of EZH2/H3K27me3 expression with clinical
and molecular characteristics
We did not find any significant correlation between
EZH2 expression and tumor stage, grading, histology
and site of origin (Additional file 1: Table S2).
None of the investigated tumor features was associ-
ated with H3K27me3 expression, with the exception of
tumor site (H3K27me3 3+ cases were indeed more fre-
quent among left-sided cancers compared with right-
sided or rectal cancers: 55 % vs. 33 % vs. 27 %; P =
0.028) (Additional file 1: Table S3). We also found a
trend toward lower H3K27me3 expression in terms of
percentage of positive cells (67.9 % vs. 57.7 %; P = 0.065)
and staining intensity (3+ cases: 28 % vs. 47 %; P =
0.052) in poorly differentiated tumors.
KRAS and BRAF genotypes were not associated with
EZH2 or H3K27me3 expression in our series.
Of note, we found a significant association between
EZH2 and H3K27me3 staining intensity (P = 0.039).
These results further corroborate the notion that higher
EZH2 expression in CRC samples results in increased
histone H3K27 methylation.
Discussion
We have already reported about the association between
the EZH2 rs3757441 C/C genotype and worse prognosis
in mCRC [8, 9] and showed that EZH2 mRNA expression
(as measured in peripheral lymphocytes) was significantly
higher among C/C patients [8]. To characterize the role of
this SNP in neoplastic cells, we analyzed EZH2 rs3757441
in normal colonic tissue (as the SNP accounts for germ-
line variation in gene sequence) and evaluated EZH2 ex-
pression in tumor cells by immunohistochemistry in a
series of 119 primary CRC. In this context, we found that
the C/C genotype was associated with significantly higher
EZH2 expression (Table 2). Potential mechanisms by
which the rs3757441 SNP may affect EZH2 expression
have been proposed elsewhere [8].
Intriguingly, we also observed a strong association be-
tween the C/C genotype and increased expression of
H3K27me3, which is the functional readout of EZH2
methylating activity. This result indicates that carriers of
the C/C genotype display higher EZH2 activity. In keep-
ing with these findings, our data suggest that higher
EZH2 expression results in increased EZH2 activation,
as measured by H3K27me3 expression, which is higher
in EZH2 3+ cases.
Among the investigated clinico-pathological features,
we observed a higher percentage of H3K27me3 cases
among left colon tumors, compared with right colon or
rectal cancers. This association was not significant for
EZH2, even though EZH2 3+ samples were more fre-
quent among left-sided tumors. It is known that right-
and left-sided CRCs differ from biological and clinical
perspectives [14, 15]: however, the small sample size of
our series suggests caution in deriving any conclusion.
Finally, we investigated if KRAS/BRAF mutations were
associated with the EZH2 pathway, finding no significant
correlation. Therefore, the suggested prognostic value of
EZH2 expression and SNP appears to be independent of
the KRAS and BRAF status: EZH2 genotyping may
therefore add additional information to the conventional
molecular profile of CRC cases.
Table 1 Specimen characteristics (n = 119)
Feature Number Percent
Tumor stage
I 5 4
II 41 34
III 52 44
IV 21 18
Tumor grade
2 76 64
3–4 43 36
Tumor site
right colon 52 44
left colon 45 38
rectum 22 18
Mucinous histology
yes 37 31
no 82 69
KRAS status
wild-type 67 56
mutant 52 44
BRAF status
wild-type 108 91
mutant 11 9
EZH2 rs3757441 genotype
C/C 5 4
C/T 51 43
T/T 63 53
EZH2 staining intensity
3+ 55 46
2+ 33 28
1+ 14 12
negative 17 14
H3K27me3 staining intensity
3+ 48 40
2+ 40 34
1+ 17 14
negative 14 12
Abbreviations: n, number; %, percentage
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In the present series, we did not investigate the associ-
ation between the EZH2 SNP or the EZH2/H3K27me3
expression and survival outcome: patient heterogeneity
in terms of disease stage, adjuvant treatments and length
of follow up might have affected the results, leading to
inconclusive or confounding findings.
Our study has several limitations that should be taken
into account in the interpretation of the results. First, we
retrieved only 5 patients with the C/C genotype for the
EZH2 rs3757441 SNP: therefore, our findings cannot be
considered definitive and further analyses should be
conducted in larger patient cohorts to confirm the asso-
ciation between EZH2 SNP variants and protein expres-
sion. Notably, the results described in the present
manuscript are in line with our previous report about
mRNA analysis on peripheral lymphocytes from CRC
patients [8]. This investigation revealed that EZH2
mRNA expression is higher in homozygous C allele car-
riers, with no difference between C/T and T/T subjects
[8]. In our opinion, these two investigations support fur-
ther evaluation of this SNP in CRC and possibly in other
malignancies. Indeed, other researchers have recently
suggested the relevance of the rs3757441 EZH2 SNP in
hepatocellular carcinoma: Yu et al. reported that patients
who carried at least one C allele have a higher lymph-
node-metastasis risk than did patients carrying the wild-
type allele [16], thus confirming the potential functional
relevance of this SNP in cancer cells. Secondly, a stan-
dardized score to evaluate EZH2 (and H3K27me3) posi-
tivity by immunohistochemistry is lacking: future studies
should thus clarify which is the preferred method to as-
sess this parameter (i.e. the percentage of positive cells,
the intensity of staining or a combination of both, as for
the SI proposed by other authors [13]).
Conclusions
To conclude, we characterized the EZH2 rs3757441
SNP, showing that the C/C variant is associated with
higher EZH2 expression and activity in the neoplastic
tissue. This SNP genotype has been linked with worse
prognosis among mCRC patients treated with chemo-
therapy with or without an anti-vascular endothelial
growth factor antibody: our data confirm in primary tu-
mors that the C allele is linked with increased EZH2 ex-
pression and activity, thus providing additional evidence
for a functional relevance of this SNP in CRC biology.
As anti-EZH2 drugs are under development and early
clinical evaluation [17], this SNP may serve as a poten-
tial predictive biomarker for such agents in CRC
patients.
Additional file
Additional file 1: Table S1: Correlation of EZH2 rs3757441 variants with
clinical and molecular characteristics. Abbreviations: %, percentage; n,
number; P, P-value. Table S2: EZH2 expression according to tumour
characteristics. Abbreviations: %, percentage; n, number; P, P-value; SD,
standard deviation; SI, Staining Index. Table S3: H3K27me3 expression
according to tumour characteristics. Abbreviations: %, percentage; n,
number; P, P-value; SD, standard deviation. (PDF 98 kb)
Abbreviations
CRC: colorectal cancer; H3K27me3: histone H3 trimethylation on lysine 27;
mCRC: metastatic colorectal cancer; PcGs: Polycomb Group genes;
PCR: polymerase chain reaction; PRCs: Polycomb Repressive Complexes;
SNPs: single-nucleotide polymorphisms.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LF, CV and FC designed the study, performed statistical analyses and drafted
the manuscript. PF and GF performed immunohistochemistry. VDG, EP, ES,
CL, GF and FC performed genetic experiments. LF, PF, CV, GM, FL, GF, YW,
RD, AF and FC supervised the data. All authors read and approved the final
manuscript.
Acknowledgements
The work was supported by funds from Fondazione ARCO Onlus (Azioni
Ricerche e Cure in Oncologia – Pisa, Italy).
Author details
1Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana,
Istituto Toscano Tumori, Pisa, Italy. 2Unit of Pathology, Department of
Surgical, Medical and Molecular Pathology and Critical Care, University of
Pisa, Pisa, Italy. 3Department of Biology, Unit of Genetics, University of Pisa,
Pisa, Italy. 4Experimental Therapeutics, BCCA Cancer Research Centre,
Vancouver, BC, Canada. 5Vancouver Prostate Centre, Vancouver, BC, Canada.
6Pharmacology Unit, Department of Clinical and Experimental Medicine,
University of Pisa, Pisa, Italy. 7Department of Life Health and Chemical
Sciences, The Open Universit, Milton Keynes, UK.
Table 2 Correlation of EZH2 rs3757441 variants with EZH2/H3K27me3 expression
EZH2 H3K27me3
3+ staining intensity % positive cells SI 4–9 3+ staining intensity % positive cells
Genotype (n) n (%) P mean (SD) P n (%) P n (%) P mean (SD) P
C/C (5) 5 (100%) 60.0 (15.8) 5 (100%) 5 (100%) 82.0% (4.472)
C/T (51) 20 (39%) 46.0 (27.7) 38 (74%) 18 (35%) 60.0% (30.53)
T/T (63) 30 (48%) 0.028 46.0 (30.3) 0.571 44 (70%) 0.328 25 (40%) 0.022 66.19% (28.54) 0.200
C/C (5) 5 (100%) 60.0% (15.8) 5 (100%) 5 (100%) 82.0% (4.472)
C/T or T/T (114) 50 (44%) 0.019 46.0% (29.1) 0.288 82 (72%) 0.322 43 (38%) 0.009 63.42% (29.47) 0.163
Abbreviations: %, percentage; n, number; P, P-value; SD, standard deviation; SI, Staining Index
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